Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 6 (June)

1. Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma.
   Br J Cancer, 92(11): 2024-31. [Abstract] [Full-text]
2. The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation.
   Cancer Res, 65(11): 4690-7. [Abstract] [Full-text]
3. Pregnancy following recurrent angiosarcoma of the ovary--a case report and review of literature.
   Gynecol Oncol, 97(3): 935-7. [Abstract] [Full-text]
4. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.
   Gynecol Oncol, 97(3): 924-7. [Abstract] [Full-text]
5. Gamma-knife radiosurgery for the treatment of ovarian cancer metastatic to the brain.
   Gynecol Oncol, 97(3): 858-61. [Abstract] [Full-text]
6. Division of pedicles by stapling during cytoreductive surgery for ovarian cancer.
   Gynecol Oncol, 97(3): 852-7. [Abstract] [Full-text]
7. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
   Gynecol Oncol, 97(3): 784-9. [Abstract] [Full-text]
8. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
   Gynecol Oncol, 97(3): 870-8. [Abstract] [Full-text]
9. Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells.
   Gynecol Oncol, 97(3): 796-806. [Abstract] [Full-text]
10. Fifth International Conference on Ovarian Cancer: challenges and opportunities.
    Gynecol Oncol, 97(3): 916-23. [Abstract] [Full-text]
11. BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
    Gynecol Oncol, 97(3): 807-12. [Abstract] [Full-text]
12. Fertility and recurrence results of conservative surgery for borderline ovarian tumors.
    Gynecol Oncol, 97(3): 845-51. [Abstract] [Full-text]
13. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
    Gynecol Oncol, 97(3): 893-7. [Abstract] [Full-text]
14. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
    Gynecol Oncol, 97(3): 898-903. [Abstract] [Full-text]
15. Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer.
    Gynecol Oncol, 97(3): 862-9. [Abstract] [Full-text]
16. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
    Gynecol Oncol, 97(3): 780-3. [Abstract] [Full-text]
17. Peritoneal tuberculosis mimicking ovarian cancer can be diagnosed by polymerase chain reaction: a case report.
    Gynecol Oncol, 97(3): 961-3. [Abstract] [Full-text]
18. Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells.
    Endocr Relat Cancer, 12(2): 407-21. [Abstract] [Full-text]
19. Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian and colon cancers.
    Fam Cancer, 4(2): 195-206. [Abstract] [Full-text]
20. Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.
    Fam Cancer, 4(2): 121-6. [Abstract] [Full-text]
21. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
    Fam Cancer, 4(2): 115-9. [Abstract] [Full-text]
22. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
    Fam Cancer, 4(2): 89-96. [Abstract] [Full-text]
23. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
    Fam Cancer, 4(2): 77-84. [Abstract] [Full-text]
24. In silico chromosomal clustering of genes displaying altered expression patterns in ovarian cancer.
    Cancer Genet Cytogenet, 160(1): 35-42. [Abstract] [Full-text]
25. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.
    Oncogene, 24(22): 3574-82. [Abstract] [Full-text]
26. Cytomorphologic features of immature ovarian teratoma in peritoneal effusion: a case report.
    Diagn Cytopathol, 33(1): 39-42. [Abstract] [Full-text]
27. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain.
    Clin Cancer Res, 11(12): 4553-60. [Abstract] [Full-text]
28. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.
    Clin Cancer Res, 11(12): 4282-8. [Abstract] [Full-text]
29. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
    Cancer Res, 65(12): 5031-7. [Abstract] [Full-text]
30. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
    Cancer Res, 65(12): 5020-6. [Abstract] [Full-text]
31. Transvaginal biopsy in the diagnosis of ovarian cancer.
    BJOG, 112(7): 991-3. [Abstract] [Full-text]
32. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.
    Cancer Gene Ther, 12(7): 593-9. [Abstract] [Full-text]
33. Short-term oral contraceptive use and the risk of epithelial ovarian cancer.
    Am J Epidemiol, 162(1): 66-72. [Abstract] [Full-text]
34. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.
    Hum Gene Ther, 16(6): 765-78. [Abstract] [Full-text]
35. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation.
    Transplant Proc, 37(5): 2185-7. [Abstract] [Full-text]
36. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
    Gynecol Oncol, 98(1): 141-5. [Abstract] [Full-text]
37. Seladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours.
    Clin Endocrinol (Oxf), 63(1): 111-5. [Abstract] [Full-text]
38. Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin.
    Eur J Cancer, 41(10): 1474-86. [Abstract] [Full-text]
39. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Ann Oncol, 16(7): 1116-22. [Abstract] [Full-text]
40. Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report.
    Gynecol Oncol, 98(1): 155-7. [Abstract] [Full-text]
41. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.
    Gynecol Oncol, 98(1): 124-8. [Abstract] [Full-text]
42. Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up.
    Gynecol Oncol, 98(1): 59-62. [Abstract] [Full-text]
43. Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: results of a multicenter retrospective Italian study.
    Gynecol Oncol, 98(1): 118-23. [Abstract] [Full-text]
44. Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.
    Gynecol Oncol, 98(1): 68-76. [Abstract] [Full-text]
45. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).
    Bone Marrow Transplant, 36(1): 25-31. [Abstract] [Full-text]
46. Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer.
    Gynecol Oncol, 98(1): 39-44. [Abstract] [Full-text]
47. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Gynecol Oncol, 98(1): 11-8. [Abstract] [Full-text]
48. A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.
    Gynecol Oncol, 98(1): 134-40. [Abstract] [Full-text]
49. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.
    Hum Genet, 117(2): 119-32. [Abstract] [Full-text]
50. Cystic ovarian teratoma with intracystic floating globules.
    Abdom Imaging, 30(3): 369-71. [Abstract] [Full-text]
51. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia.
    Blood, 106(1): 362-7. [Abstract] [Full-text]
52. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion.
    Mod Pathol, 18(7): 903-11. [Abstract] [Full-text]
53. Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells.
    Oncogene, 24(27): 4388-400. [Abstract] [Full-text]
54. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
    J Gene Med, 7(7): 898-907. [Abstract] [Full-text]
55. Models of ovarian cancer--are we there yet?
    Mol Cell Endocrinol, 239(1): 15-26. [Abstract] [Full-text]
56. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2.
    Mol Carcinog, 43(3): 141-54. [Abstract] [Full-text]
57. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization--meta-analysis and Bayesian analysis.
    Radiology, 236(1): 85-94. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.